Viridian Therapeutics(VRDN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data - Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in December 2024 - - Initiated two global phase 3 clinical trials of subcutaneous VRDN-003, REVEAL-1 and REVEAL-2 in August, in active and chronic TED, respectively; topline data anticipated in the first ...